Trastuzumab emtansine for advanced HER2-positive breast cancer and beyond: genome landscape-based targets

被引：0
作者：
Cho, William C. S. [1 ]
Roukos, Dimitrios H. [2 ]
机构：
[1] Queen Elizabeth Hosp, Dept Clin Oncol, Hong Kong, Hong Kong, Peoples R China
[2] GenNetMed Ioannina Univ, Ctr Biosyst & Genom Network Med CBS, Ioannina, Greece
来源：
EXPERT REVIEW OF ANTICANCER THERAPY | 2013年 / 13卷 / 01期
关键词：
breast cancer; drugs; genome; HER2-positive; trastuzumab; trastuzumab emtansine; NEXT-GENERATION; PHASE-II; ARCHITECTURE; LAPATINIB; PLUS;
D O I：
10.1586/ERA.12.152
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：5 / 8
页数：4
相关论文
共 50 条
  • [11] Trastuzumab emtansine (Kadcyla®) approval in HER2-positive metastatic breast cancers
    Guerin, Mathilde
    Sabatier, Renaud
    Goncalves, Anthony
    BULLETIN DU CANCER, 2015, 102 (04) : 390 - 397
  • [12] Trastuzumab deruxtecan versus trastuzumab emtansine in Asian patients with HER2-positive metastatic breast cancer
    Iwata, Hiroji
    Xu, Binghe
    Kim, Sung-Bae
    Chung, Wei-Pang
    Park, Yeon Hee
    Kim, Min Hwan
    Tseng, Ling-Ming
    Chung, Chi-Feng
    Huang, Chiun-Sheng
    Kim, Jee Hyun
    Chiu, Joanne Wing Yan
    Yamashita, Toshinari
    Li, Wei
    Egorov, Anton
    Nishijima, Soichiro
    Nakatani, Shunsuke
    Nishiyama, Yuji
    Sugihara, Masahiro
    Cortes, Javier
    Im, Seock-Ah
    CANCER SCIENCE, 2024, 115 (09) : 3079 - 3088
  • [13] Trastuzumab emtansine in the treatment of HER2-positive metastatic breast cancer in Japanese patients
    Sawaki, Masataka
    BREAST CANCER-TARGETS AND THERAPY, 2014, 6 : 37 - 41
  • [14] The success story of trastuzumab emtansine, a targeted therapy in HER2-positive breast cancer
    Dieras, Veronique
    Bachelot, Thomas
    TARGETED ONCOLOGY, 2014, 9 (02) : 111 - 122
  • [15] Beyond trastuzumab: New treatment options for HER2-positive breast cancer
    Saini, Kamal S.
    Azim, Hatem A., Jr.
    Metzger-Filho, Otto
    Loi, Sherene
    Sotiriou, Christos
    de Azambuja, Evandro
    Piccart, Martine
    BREAST, 2011, 20 : S20 - S27
  • [16] Profiling and targeting HER2-positive breast cancer using trastuzumab emtansine
    Sadeghi, Saeed
    Olevsky, Olga
    Hurvitz, Sara A.
    PHARMACOGENOMICS & PERSONALIZED MEDICINE, 2014, 7 : 329 - 338
  • [17] Trastuzumab beyond progression in HER2-positive metastatic breast cancer
    Al-Naqqash, Manwar
    Jasim Al-Serarati, Waleed
    Farooq Kareem, Tara
    BREAST JOURNAL, 2021, 27 (03) : 297 - 299
  • [18] Trastuzumab deruxtecan in HER2-positive metastatic breast cancer and beyond
    Perez, Jose
    Garrigos, Laia
    Gion, Maria
    Janne, Pasi A.
    Shitara, Kohei
    Siena, Salvatore
    Cortes, Javier
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (07) : 811 - 824
  • [19] Beyond trastuzumab: novel therapeutic strategies in HER2-positive metastatic breast cancer
    R Y Tsang
    R S Finn
    British Journal of Cancer, 2012, 106 : 6 - 13
  • [20] Trastuzumab emtansine: a novel antibody-drug conjugate for HER2-positive breast cancer
    Burris, Howard A., III
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2011, 11 (06) : 807 - 819
12345